Form 8-K - Current report:
SEC Accession No. 0000950170-25-023742
Filing Date
2025-02-20
Accepted
2025-02-20 07:45:37
Documents
13
Period of Report
2025-02-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rgen-20250220.htm   iXBRL 8-K 48601
2 EX-99.1 rgen-ex99_1.htm EX-99.1 1019436
3 GRAPHIC img109360391_0.jpg GRAPHIC 5520
  Complete submission text file 0000950170-25-023742.txt   1234264

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgen-20250220.xsd EX-101.SCH 27847
16 EXTRACTED XBRL INSTANCE DOCUMENT rgen-20250220_htm.xml XML 4509
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 25643307
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)